Factors predictive of parametrial boost in patients with cervical cancer treated with definitive chemoradiation

•Parametrial boost (PMB) is indicated for persistent parametrial and pelvic sidewall disease. This study aims to identify demographic, clinical, and treatment-related characteristics associated with treatment of PMB. Two factors were found significant: pelvic sidewall invasion at diagnosis and more...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology reports 2022-02, Vol.39, p.100919-100919, Article 100919
Main Authors: Jamora, Kurl E., Patricia A. Cañal, Johanna
Format: Article
Language:English
Subjects:
Cervical cancer
Parametrial boost
Research Report
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Parametrial boost (PMB) is indicated for persistent parametrial and pelvic sidewall disease. This study aims to identify demographic, clinical, and treatment-related characteristics associated with treatment of PMB. Two factors were found significant: pelvic sidewall invasion at diagnosis and more chemotherapy cycles received. No significant difference in outcomes was observed between those treated with PMB and not. The aim of this study is to identify demographic, clinical, and treatment-related characteristics associated with the prescription of parametrial boost (PMB) in cervical cancer patients undergoing definitive chemoradiation. A retrospective chart review of 132 non-metastatic cervical cancer patients treated with definitive chemoradiation from May 2017 to December 2019 was performed. Demographic, clinical, and treatment characteristics were obtained and compared between those who received PMB and those who did not. Clinical outcomes (pelvic recurrence, tumor persistence, distant metastases, and median survival time) were also gathered and compared. Statistical software was used for analysis, with a p 
ISSN:2352-5789
2352-5789
DOI:10.1016/j.gore.2021.100919